Ending rational disengagement: Bridging the strategy-reality gap

The gap between field and brand teams is often framed as a communication problem that can be solved with alignment summits or new tech deployments. However, the reality is more complex and represents a fundamental shift in structural alignment. Timelines differ. Workflows and tools vary. Distinct performance mandates drive divergent metric selection and channel behaviour. That leaves companies with two teams holding conflicting definitions of what success looks like.

Standard remedies like cross-functional workshops and shared dashboards will not overcome the root causes of these challenges. Instead, pharma companies must shift from reporting static data that looks at channel-by-channel data to sourcing conversational performance answers that can connect across field and digital channels. By empowering brand strategy and field execution teams with clear and powerful orchestration deployments that use embedded tools, organisations can increase completion rates and cross-functional collaboration.

Different slices of the same reality

The timelines and information sets used by brand strategy and field sales teams are vastly different, making misalignment a structural feature of many pharmaceutical companies. The first issue is that brand teams think on an annual basis and rely heavily on digital metrics – such as clicks, email opens, and engagement rates – because they lack a real-time feedback loop from the field (and from most agency and vendor partners).

The second aspect is that field teams think in quarterly cycles, optimising their campaigns for prescribing behaviour change within a shorter period and based on their experience. At the same time, the functional priorities of a salesperson differ fundamentally from those of a marketing or digital team member.

Neither team is wrong, nor acting irrationally. Both are doing what the functional structures of their roles reward. But they are looking at different elements of the same reality.

This issue is compounded because the divergence in perspectives is invisible to those affected by them. Too often, brand teams seek to understand field dynamics, but struggle to align strategies with ground-level insights, resulting in field teams receiving content that feels misaligned with immediate prescriber needs. Over time, this leads to rational disengagement, which can manifest as cultural resistance. As the gap between headquarter strategy and rep experience widens, resistance becomes more entrenched. No technological deployment alone can dissolve this type of resistance.

The potential for misalignment intensifies at organisational inflection points. In companies scaling from specialty to primary care, the size of field teams begins to outpace a brand’s capacity to personalise. In rare disease companies preparing a first launch, small field teams operate in an environment where physician relationships are unusually consequential and the lack of similarity between medical affairs and commercial teams is likely to be most extreme.

Barriers to technology adoption

The default commercial technology procurement cycle follows a predictable pattern: choose a platform, configure it, train the field, and measure adoption. Diagnosing underperformance becomes an afterthought because adoption friction is addressed at the end of the process, rather than at the beginning.

When a platform relies on a "spray and pray" delivery model and requires field reps to open separate portals or navigate third-party interfaces, it creates an immediate barrier. Vendor success dependent on extra logins fundamentally conflicts with rep productivity from day one. To overcome this rational disengagement, software must execute within existing CRM and Veeva workflows, routing recommendations directly into upstream daily operations.

By embedding decisioning into native tools, commercial platforms direct and orchestrate rep behaviors without disrupting field execution.

A lack of medical-commercial data integration

The business case for orchestration typically relies on platform ROI; for example, digital channel efficiency, cost per touchpoint, and content utilisation. However, when faced with narrow physician-access and complex clinical pathways, just one meaningful interaction can shift prescribing behaviour in ways that a dozen digital touchpoints cannot.

Vital opportunities in these interactions are lost when reps spend too much time just determining basic information, instead of learning what customers care about. This friction makes the difference between a rep who engages as a clinical partner and one who is still orienting when the appointment ends.

Effective hypothesis generation relies on not just cross-channel signal aggregation, but a level of cross-commercial data integration and a tool that acts as an air traffic controller for complex data streams – a structure that most organisations have not attempted and many have not even mapped. Unifying this data transforms marketing from a simple content generator into a hypothesis-tester, shifting the focus to true prescriber-engagement efficacy, rather than superficial email open rates. A single, connected decision model across field sales and digital marketing allows teams to move seamlessly from an NPI-level performance answer to a governed execution loop.

Overcoming operational challenges

An orchestration engine is only as effective as the operational foundation beneath it. Evaluating these tools requires assessing two core criteria: whether the deployment connects directly to each team’s performance goals, and whether it operates entirely inside established workflows.

Achieving field buy-in requires demonstrating clear alignment with core metrics, rather than relying on town hall announcements or training decks. Once aligned, intelligence platforms should route recommendations straight into active CRM interfaces.

Instead of delivering passive engagement metrics, orchestration must equip reps with actionable customer insights. For example, rather than flagging generic account movement, the system provides explicit direction: "Prescriber Y has engaged with three high-scientific digital assets regarding safety profiles in the last 14 days, but has had zero field touchpoints; prioritise a clinical discussion on our updated head-to-head safety data on your next visit." Shifting to real-time, answer-to-action loops allows teams to test hypotheses during interactions and convert raw measurement into governed execution.

This transition from fragmented reporting to a governed, answer-to-action engine is how organisations finally bridge the gap between their strategy and the rep’s reality.

The readiness gap

These issues reveal an uncomfortable truth for an industry that has invested heavily in omnichannel approaches. The problem is not a lack of effective tools, but the absence of a framework to verify whether an organisation has sufficient field buy-in to justify deploying them.

This creates a cycle of failure. Organisations invest in platforms designed to solve a coordination problem they do not fully understand. There is inevitably low adoption. The subsequent performance gap is attributed to the platform, triggering yet another procurement cycle. And the whole process starts all over again.

We need to consider the possibility that the technology is working as it was designed to. Organisations simply aren’t ready to deploy it effectively.

An actionable sequence and aspirational endpoint

An actionable sequence can overcome this readiness gap: the first step is to audit whether field execution teams understand the strategic rationale behind digital initiatives and how they connect to their core performance goals. The second is to assess whether operational objectives align. Third, verify that proposed tools execute within existing workflows and, fourth, define outputs as hypothesis-equipped reps, rather than simple engagement metrics. Under this framework, measurement becomes an active, governed answer-to-action cycle where proposed adjustments are previewed and routed to the correct workflow owner.

This approach doesn’t immediately resolve structural misalignment, but it can produce results within existing structures. The aspirational endpoint? Making field and brand teams truly coherent and focused directly on patient-centric metrics. Field-brand misalignment is fundamentally a perspective problem, as both functions rationally optimise for different time horizons. To overcome this, organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

About the author

Stephen Onikoro is a member of the founding team and now serves as chief operating officer at PharmaForceIQ, an optichannel engagement solutions provider. He oversees operational functions and client relationships with medical and marketing teams at small to large pharmaceutical companies. He is a life sciences commercialisation strategy expert, with more than 15 years of experience in management consulting, with a focus on pre-commercial strategy at BeiGene prior to PharmaForceIQ and on commercial strategy in prior roles at PwC, Deloitte, and IQVIA.